Clinical Trial Update: Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating regression of liver fibrosis with Tenofovir Alafenamide (TAF) in chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Jidong Jia | Conditions: Chronic Hepatitis B | Phase 4 | Status: UNKNOWN